Your browser doesn't support javascript.
loading
Sequential inverse dysregulation of the RNA helicases DDX3X and DDX3Y facilitates MYC-driven lymphomagenesis.
Gong, Chun; Krupka, Joanna A; Gao, Jie; Grigoropoulos, Nicholas F; Giotopoulos, George; Asby, Ryan; Screen, Michael; Usheva, Zelvera; Cucco, Francesco; Barrans, Sharon; Painter, Daniel; Zaini, Nurmahirah Binte Mohammed; Haupl, Björn; Bornelöv, Susanne; Ruiz De Los Mozos, Igor; Meng, Wei; Zhou, Peixun; Blain, Alex E; Forde, Sorcha; Matthews, Jamie; Khim Tan, Michelle Guet; Burke, G A Amos; Sze, Siu Kwan; Beer, Philip; Burton, Cathy; Campbell, Peter; Rand, Vikki; Turner, Suzanne D; Ule, Jernej; Roman, Eve; Tooze, Reuben; Oellerich, Thomas; Huntly, Brian J; Turner, Martin; Du, Ming-Qing; Samarajiwa, Shamith A; Hodson, Daniel J.
Afiliación
  • Gong C; Wellcome-MRC Cambridge Stem Cell Institute, University of Cambridge, Puddicombe Way, Cambridge CB2 0AW, UK; Department of Haematology, University of Cambridge, Cambridge CB2 0AW, UK.
  • Krupka JA; Wellcome-MRC Cambridge Stem Cell Institute, University of Cambridge, Puddicombe Way, Cambridge CB2 0AW, UK; Department of Haematology, University of Cambridge, Cambridge CB2 0AW, UK; MRC Cancer Unit, University of Cambridge, Hutchison/MRC Research Centre, Cambridge CB2 0XZ, UK.
  • Gao J; Wellcome-MRC Cambridge Stem Cell Institute, University of Cambridge, Puddicombe Way, Cambridge CB2 0AW, UK; Department of Haematology, University of Cambridge, Cambridge CB2 0AW, UK.
  • Grigoropoulos NF; Department of Haematology, Singapore General Hospital, Singapore, Singapore.
  • Giotopoulos G; Wellcome-MRC Cambridge Stem Cell Institute, University of Cambridge, Puddicombe Way, Cambridge CB2 0AW, UK; Department of Haematology, University of Cambridge, Cambridge CB2 0AW, UK.
  • Asby R; Wellcome-MRC Cambridge Stem Cell Institute, University of Cambridge, Puddicombe Way, Cambridge CB2 0AW, UK; Department of Haematology, University of Cambridge, Cambridge CB2 0AW, UK.
  • Screen M; Immunology Programme, The Babraham Institute, Cambridge CB22 3AT, UK.
  • Usheva Z; Wellcome-MRC Cambridge Stem Cell Institute, University of Cambridge, Puddicombe Way, Cambridge CB2 0AW, UK; Department of Haematology, University of Cambridge, Cambridge CB2 0AW, UK.
  • Cucco F; Division of Cellular and Molecular Pathology, Department of Pathology, University of Cambridge, Cambridge CB20QQ, UK.
  • Barrans S; Haematological Malignancy Diagnostic Service, St. James's Institute of Oncology, Leeds LS9 7TF, UK.
  • Painter D; Epidemiology and Cancer Statistics Group, Department of Health Sciences, University of York, York YO10 5DD, UK.
  • Zaini NBM; Department of Haematology, Singapore General Hospital, Singapore, Singapore.
  • Haupl B; Department of Medicine II, Hematology/Oncology, Goethe University, Theodor-Stern-Kai 7, 60590 Frankfurt, Germany; German Cancer Research Center and German Cancer Consortium, Heidelberg, Germany; Frankfurt Cancer Institute, Goethe University Frankfurt, 60596 Frankfurt, Germany.
  • Bornelöv S; Wellcome-MRC Cambridge Stem Cell Institute, University of Cambridge, Puddicombe Way, Cambridge CB2 0AW, UK.
  • Ruiz De Los Mozos I; The Francis Crick Institute, London NW1 1AT, UK; Department for Neuromuscular Diseases, UCL Queen Square Institute of Neurology, London WC1N 3BG, UK.
  • Meng W; School of Biological Sciences, Nanyang Technological University, 60 Nanyang Drive, Singapore, Singapore.
  • Zhou P; National Horizons Centre, Teesside University, 38 John Dixon Lane, Darlington DL1 1HG, UK; School of Health & Life Sciences, Teesside University, Middlesbrough TS1 3BA, UK.
  • Blain AE; National Horizons Centre, Teesside University, 38 John Dixon Lane, Darlington DL1 1HG, UK; Wolfson Childhood Cancer Research Centre, Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, UK; School of Health & Life Sciences, Teesside University, Middlesbrough TS1 3BA
  • Forde S; Division of Cellular and Molecular Pathology, Department of Pathology, University of Cambridge, Cambridge CB20QQ, UK.
  • Matthews J; Division of Cellular and Molecular Pathology, Department of Pathology, University of Cambridge, Cambridge CB20QQ, UK.
  • Khim Tan MG; Department of Clinical Translational Research, Singapore General Hospital, Outram Road, Singapore 169856, Singapore.
  • Burke GAA; Department of Paediatric Oncology, Addenbrooke's Hospital, Cambridge, UK.
  • Sze SK; School of Biological Sciences, Nanyang Technological University, 60 Nanyang Drive, Singapore, Singapore.
  • Beer P; Wellcome Trust Sanger Institute, Hinxton, Cambridge CB10 1SA, UK.
  • Burton C; Haematological Malignancy Diagnostic Service, St. James's Institute of Oncology, Leeds LS9 7TF, UK.
  • Campbell P; Wellcome Trust Sanger Institute, Hinxton, Cambridge CB10 1SA, UK.
  • Rand V; National Horizons Centre, Teesside University, 38 John Dixon Lane, Darlington DL1 1HG, UK; School of Health & Life Sciences, Teesside University, Middlesbrough TS1 3BA, UK.
  • Turner SD; Division of Cellular and Molecular Pathology, Department of Pathology, University of Cambridge, Cambridge CB20QQ, UK; CEITEC, Masaryk University, Brno, Czech Republic.
  • Ule J; The Francis Crick Institute, London NW1 1AT, UK; Department for Neuromuscular Diseases, UCL Queen Square Institute of Neurology, London WC1N 3BG, UK.
  • Roman E; Epidemiology and Cancer Statistics Group, Department of Health Sciences, University of York, York YO10 5DD, UK.
  • Tooze R; Haematological Malignancy Diagnostic Service, St. James's Institute of Oncology, Leeds LS9 7TF, UK; Section of Experimental Haematology, Leeds Institute of Molecular Medicine, University of Leeds, Leeds LS2 9JT, UK.
  • Oellerich T; Department of Medicine II, Hematology/Oncology, Goethe University, Theodor-Stern-Kai 7, 60590 Frankfurt, Germany; German Cancer Research Center and German Cancer Consortium, Heidelberg, Germany; Frankfurt Cancer Institute, Goethe University Frankfurt, 60596 Frankfurt, Germany.
  • Huntly BJ; Wellcome-MRC Cambridge Stem Cell Institute, University of Cambridge, Puddicombe Way, Cambridge CB2 0AW, UK; Department of Haematology, University of Cambridge, Cambridge CB2 0AW, UK.
  • Turner M; Immunology Programme, The Babraham Institute, Cambridge CB22 3AT, UK.
  • Du MQ; Division of Cellular and Molecular Pathology, Department of Pathology, University of Cambridge, Cambridge CB20QQ, UK.
  • Samarajiwa SA; MRC Cancer Unit, University of Cambridge, Hutchison/MRC Research Centre, Cambridge CB2 0XZ, UK.
  • Hodson DJ; Wellcome-MRC Cambridge Stem Cell Institute, University of Cambridge, Puddicombe Way, Cambridge CB2 0AW, UK; Department of Haematology, University of Cambridge, Cambridge CB2 0AW, UK. Electronic address: djh1002@cam.ac.uk.
Mol Cell ; 81(19): 4059-4075.e11, 2021 10 07.
Article en En | MEDLINE | ID: mdl-34437837
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Linfocitos B / Antígenos de Histocompatibilidad Menor / Linfoma de Células B / Proteínas Proto-Oncogénicas c-myc / ARN Helicasas DEAD-box / Proteínas de Neoplasias Límite: Adolescent / Adult / Aged / Aged80 / Animals / Child / Child, preschool / Female / Humans / Male Idioma: En Revista: Mol Cell Asunto de la revista: BIOLOGIA MOLECULAR Año: 2021 Tipo del documento: Article País de afiliación: Reino Unido
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Linfocitos B / Antígenos de Histocompatibilidad Menor / Linfoma de Células B / Proteínas Proto-Oncogénicas c-myc / ARN Helicasas DEAD-box / Proteínas de Neoplasias Límite: Adolescent / Adult / Aged / Aged80 / Animals / Child / Child, preschool / Female / Humans / Male Idioma: En Revista: Mol Cell Asunto de la revista: BIOLOGIA MOLECULAR Año: 2021 Tipo del documento: Article País de afiliación: Reino Unido